Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer

A genetically engineered mouse model of NOTCH-mutant SCLC reveals that nonneuroendocrine plasticity persists in the absence of NOTCH, driven by a RUNX2-REST–dependent pathway and innate immune signaling. Neuroendocrine to nonneuroendocrine plasticity supports small cell lung cancer (SCLC) tumorigenesis and promotes immunogenicity. Approximately 20% to 25% of SCLCs harbor loss-of-function (LOF) NOTCH mutations. Previous studies demonstrated that NOTCH functions as a SCLC tumor suppressor, but can also drive nonneuroendocrine plasticity to support SCLC growth. Given the dual functionality of NOTCH, it is not understood why SCLCs select for LOF NOTCH mutations and how these mutations affect SCLC tumorigenesis. In a CRISPR-based genetically engineered mouse model of SCLC, genetic loss of Notch1 or Notch2 modestly accelerated SCLC tumorigenesis. Interestingly, Notch-mutant SCLCs still formed nonneuroendocrine subpopulations, and these Notch-independent, nonneuroendocrine subpopulations were driven by Runx2-mediated regulation of Rest. Notch2-mutant nonneuroendocrine cells highly express innate immune signaling genes including stimulator of interferon genes (STING) and were sensitive to STING agonists. This work identifies a Notch-independent mechanism to promote nonneuroendocrine plasticity and suggests that therapeutic approaches to activate STING could be selectively beneficial for SCLCs with NOTCH2 mutations. Significance: A genetically engineered mouse model of NOTCH-mutant SCLC reveals that nonneuroendocrine plasticity persists in the absence of NOTCH, driven by a RUNX2-REST–dependent pathway and innate immune signaling.

[1]  Anna L. Brown,et al.  Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer , 2021, Nature Communications.

[2]  V. Quaranta,et al.  ASCL1 represses a SOX9+ neural crest stem-like state in small cell lung cancer , 2021, Genes & development.

[3]  C. Paweletz,et al.  Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. , 2021, Cancer discovery.

[4]  P. Robson,et al.  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. , 2021, Cancer cell.

[5]  J. Sage.  Faculty Opinions recommendation of SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: A comprehensive immunohistochemical and histopathologic characterization. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[6]  A. Tan,et al.  Identification of RUNX1T1 as a potential epigenetic modifier in small‐cell lung cancer , 2020, Molecular oncology.

[7]  T. Billiar,et al.  Notch signaling protects CD4 T cells from STING-mediated apoptosis during acute systemic inflammation , 2020, Science Advances.

[8]  Gabor Marth,et al.  MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. , 2020, Cancer cell.

[9]  Z. Lou,et al.  Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC , 2020, Clinical Cancer Research.

[10]  L. Girard,et al.  A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity , 2020, Nature Cancer.

[11]  Clifford A. Meyer,et al.  Lisa: inferring transcriptional regulators through integrative modeling of public chromatin accessibility and ChIP-seq data , 2020, Genome Biology.

[12]  Zachary T Herbert,et al.  The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis , 2019, Genes & development.

[13]  M. Krasnow,et al.  Rare Pulmonary Neuroendocrine Cells Are Stem Cells Regulated by Rb, p53, and Notch , 2019, Cell.

[14]  H. Ji,et al.  Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest. , 2019, Biochemical and biophysical research communications.

[15]  T. Graeber,et al.  Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. , 2019, Cancer cell.

[16]  V. Petrilli,et al.  [Cytosolic DNA sensing by the cGAS-STING pathway in cancer]. , 2019, Medecine sciences : M/S.

[17]  Joshua M. Korn,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[18]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[19]  O. Elemento,et al.  Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells , 2019, The Journal of experimental medicine.

[20]  C. Rudin,et al.  Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition , 2019, Science Signaling.

[21]  Xiaoyan Zhang,et al.  Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis , 2018, Nucleic Acids Res..

[22]  D. Spector,et al.  POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer , 2018, Genes & development.

[23]  P. Tamayo,et al.  Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses , 2018, Nature Medicine.

[24]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[25]  Tao Liu,et al.  Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse , 2016, Nucleic Acids Res..

[26]  Luc Girard,et al.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.

[27]  A. Gazdar,et al.  Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer , 2016, Genes & development.

[28]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[29]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[30]  T. Jacks,et al.  The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  Tao Wang,et al.  ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers , 2014, Proceedings of the National Academy of Sciences.

[32]  Jon C. Aster,et al.  NOTCH1–RBPJ complexes drive target gene expression through dynamic interactions with superenhancers , 2013, Proceedings of the National Academy of Sciences.

[33]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[34]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[35]  A. Berns,et al.  A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. , 2011, Cancer cell.

[36]  A. Sweet-Cordero,et al.  Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. , 2010, Cancer research.

[37]  S. Hou,et al.  JAK–STAT is restrained by Notch to control cell proliferation of the Drosophila intestinal stem cells , 2010, Journal of cellular biochemistry.

[38]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[39]  M. Brock,et al.  Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. , 2009, Cancer research.

[40]  B. Shilo,et al.  Drosophila follicle cells are patterned by multiple levels of Notch signaling and antagonism between the Notch and JAK/STAT pathways , 2007, Development.

[41]  S. Ogawa,et al.  AML1/Runx1 rescues Notch1-null mutation-induced deficiency of para-aortic splanchnopleural hematopoiesis. , 2006, Blood.

[42]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[43]  Douglas W. Ball,et al.  Notch Signaling Induces Rapid Degradation of Achaete-Scute Homolog 1 , 2002, Molecular and Cellular Biology.

[44]  S. Baylin,et al.  Notch signaling induces cell cycle arrest in small cell lung cancer cells. , 2001, Cancer research.